Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05279092

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

Led by Yale University · Updated on 2025-05-14

250

Participants Needed

2

Research Sites

285 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

D

Department of Anesthesiology Faculty Development Fund

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.

CONDITIONS

Official Title

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • American Society of Anesthesiologists status I, II, or III
  • Elective, primary, unilateral total knee arthroplasty planned for spinal anesthesia with plain 0.5% bupivacaine
Not Eligible

You will not qualify if you...

  • Refusal of consent
  • Pregnancy
  • Inability to complete follow-up questionnaires due to cognitive dysfunction, psychiatric disorder, language barrier, or lack of internet access
  • Coagulopathy
  • Allergy or intolerance to acetaminophen, Celebrex, bupivacaine, dexamethasone, methylprednisolone acetate, or liposomal bupivacaine
  • Use of any opioids within one month before surgery or regular marijuana use more than once per month
  • Insulin-dependent or uncontrolled diabetes with day-of-surgery blood glucose >200 mg/dl or HbA1C > 8.0%
  • Infection at peripheral nerve block site or systemic infection
  • Immune compromise such as HIV or chronic glucocorticoid use
  • Severe pre-existing neuropathy
  • Total knee arthroplasty for reasons other than osteoarthritis, history of surgery on the same knee, revision or bilateral TKA
  • Severe liver or kidney dysfunction with glomerular filtration rate <50 ml/min
  • Body weight less than 60 kg
  • Active or latent peptic ulcers, diverticulitis, recent intestinal anastomoses, or non-specific ulcerative colitis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Yale New Haven Hospital Saint Raphael Campus

New Haven, Connecticut, United States, 06520

Actively Recruiting

2

Yale New Haven Hospital York Street Campus

New Haven, Connecticut, United States, 06520

Actively Recruiting

Loading map...

Research Team

J

Jinlei Li, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here